Now the therascreen EGFR test covers even more clinically validated mutations to deliver more of the valuable information you need to make the best therapeutic decisions.
With the recent approval of GILOTRIF to treat patients with additional EGFR mutations, our therascreen EGFR test now covers even more actionable mutations, and helps treat an even broader group of NSCLC patients.
![9850_EGFR[2]-EDIT2](https://www.egfrbyqiagen.com/wp-content/uploads/9850_EGFR2-EDIT2.svg)
* Analytically validated mutations with clinical outcome data from LUX-Lung 2, LUX-Lung 6, LUX-Lung 3, IFUM, AURA2 and EURTAC clinical trials.
†S therascreen EGFR RGQ PCR Kit Instructions for Use (Handbook)SDownload handbook
QIAGEN’s lung cancer solutions offer many benefits, including convenient, efficient and precise EGFR testing, reliable, rapid and cost effective workflows, and secure systems with experienced services and support.
The therascreen EGFR RGQ PCR Kit (therascreen EGFR test) reliably detects mutations in the EGFR oncogene which are found in lung cancer. EGFR testing is used to select NSCLC patients who are being considered for treatment with either GILOTRIF (afatinib) or IRESSA (gefitinib).
QIAGEN’s therascreen mutation detection tests help determine what treatment options may be best for cancer patients. Find out which labs are using the therascreen EGFR RGQ PCR Kit and other therascreen biomarker tests!
